What the Chemical Industry Didn’t Want You to Know

Tucked away in an Oregon barn for decades was a collection of internal documents, correspondence, and chemical safety studies detailing the lengths the chemical industry took to conceal the dangers of their products.  

The documents in this collection—dubbed the “Poison Papers”—allege fraudulent chemical safety testing, corporate concealment of chemical dangers, and collusion between the industry and the regulators who were supposed to be protecting the public and environment. Commonly used herbicides like Roundup (glyphosate), dicamba, atrazine, and 2,4-D feature prominently among the papers, as do nearly every large chemical corporation. 

Now, thanks to the combined efforts of the Center for Media and Democracy (CMD) and the Bioscience Resource Project (BRP), this collection is available online for the first time….

The Poison Papers are the digitization of about three tons of files from litigation against Monsanto, litigation involving some of the Dow Chemicals products, open records requests, and Freedom of Information Act requests to the federal government as well as state agencies. It represents documents that were discovered over the past 40 years but some of the documents, including scientific studies, are older than that because they are from litigation….”

Mindray Signs Patient Safety Movement’s Open Data Pledge & Becomes 90th Company to Join to Improve Patient Safety | Business Wire

The Patient Safety Movement Foundation (PSMF) announced today that the global medical device developer and manufacturer Mindray has become the 90th company to sign the PSMF’s Open Data Pledge, demonstrating its commitment to improving patient safety through data sharing….”

Mindray Signs Patient Safety Movement’s Open Data Pledge & Becomes 90th Company to Join to Improve Patient Safety | Business Wire

The Patient Safety Movement Foundation (PSMF) announced today that the global medical device developer and manufacturer Mindray has become the 90th company to sign the PSMF’s Open Data Pledge, demonstrating its commitment to improving patient safety through data sharing….”

THE OPEN GOVERNMENT PARTNERSHIP: FOURTH OPEN GOVERNMENT NATIONAL ACTION PLAN FOR THE UNITED STATES OF AMERICA, February 2019

“This roadmap for the next two years outlines a selection of Trump Administration objectives to make government information more open and accessible for developers, academics, entrepreneurs and everyday Americans….

3) Provide Public Access to Federally Funded Research

Primarily through the National Science and Technology Council (Council), the White House Office of Science and Technology Policy coordinates United States efforts to make the results of Federally funded scientific research more accessible and useful to the public, industry, and the scientific community. In the Council’s Subcommittee on Open Science, thirty-two United States agency funders collaborate to improve the preservation, discoverability, accessibility, and usability of Federally funded scientific research, with the aims of bolstering the reliability of that research, accelerating scientific discovery, stimulating innovation, enhancing economic growth and job creation.

In 2018, the Subcommittee on Open Science was re-chartered to promote open science principles across the Federal Government and increase public access to Federally-funded research results. The Subcommittee’s priorities include: (1) Facilitating coordination across Federal Government agencies on open science efforts; (2) Developing appropriate incentives to encourage researchers to adopt open science principles; (3) Streamlining and synchronizing agency and researcher data management practices for maximum utility to the public; (4) Collaborating with academia, researcher communities, and industry toward the development of research data standards that further open science. As part of the Subcommittee’s objectives, it will develop a report that provides recommendations for improvements to existing Federal open access policies and continued collaboration between agencies on achieving open access objectives….”

Production and uptake of Open Access publications involving the private sector: the case of big pharma

Abstract:  Over the last years Open Access has been ranked very high on science policy agenda’s both internationally as well as nationally. This resulted in many national mandates and international guidelines on OA publishing of scientific results. One of the reasons OA has been pushed so strongly by science policy is found in the argument that what is financed publicly, should be publicly available. This argument, also known as the ‘tax payers argument’ is used to support and legitimize the push for open accessibility, not only of scientific publications, but also of the underlying research data, in order to guarantee the nonacademic sector, with lower degrees of accessibility to otherwise ‘behind-the-paywall’ information, access to outcomes of scientific research in the public sector. In this study we will focus on the developments in the OA publishing in one particular institutional sector, the private sector. Business enterprises represent the main sector in terms of R&D investments. According to Eurostat, in the year 2016 this sector represented 65% of the total R&D expenditures within the EU28. While objectives and incentives in the private sector might not always been aligned with the disclosure of research results in the open scientific literature, there is no doubt that this is the main actor when it comes to R&D performance. Within the business sector, we will focus our study in the pharmaceutical sector, by selecting a number of large pharmaceutical companies. Pharmaceutical companies represent an interesting case of study, given that is it one of the most R&D intensive industries, while it si also known for its shift in R&D orientation, from an in-house focus in the development of R&D towards a model much more open and collaborative, with more interactions with academic partners and other companies. Despite the importance of industrial R&D, until now it remains relatively understudied how private sector institutions which are active in R&D have embraced the OA movement, hence it remains relatively unknown how the private sector adapts to and can benefit from the new paradigm of open scholarship. Our objective is to shed more light on the extent to which big pharma both has been publishing in OA and also has been benefiting from OA publications to build their own research.

Big pharma is embracing open-access publishing like never before

“Scientists who work in the pharmaceutical industry have begun to publish a higher proportion of their papers open access than academics who aren’t in industry, according to an analysis.

In a literature analysis, researchers found that the proportion of open-access papers published by 23 large drug companies, such as Pfizer and Roche, almost doubled between 2009 and 2016, and has overtaken the proportion of freely available papers published generally in medicine-related fields. The study was posted to the SocArXiv preprint server on 7 February1….”

roduction and uptake of Open Access publications involving the private sector: the case of big pharma

Abstract:  Over the last years Open Access has been ranked very high on science policy agenda’s both internationally as well as nationally. This resulted in many national mandates and international guidelines on OA publishing of scientific results. One of the reasons OA has been pushed so strongly by science policy is found in the argument that what is financed publicly, should be publicly available. This argument, also known as the ‘tax payers argument’ is used to support and legitimize the push for open accessibility, not only of scientific publications, but also of the underlying research data, in order to guarantee the nonacademic sector, with lower degrees of accessibility to otherwise ‘behind-the-paywall’ information, access to outcomes of scientific research in the public sector. In this study we will focus on the developments in the OA publishing in one particular institutional sector, the private sector. Business enterprises represent the main sector in terms of R&D investments. According to Eurostat, in the year 2016 this sector represented 65% of the total R&D expenditures within the EU28. While objectives and incentives in the private sector might not always been aligned with the disclosure of research results in the open scientific literature, there is no doubt that this is the main actor when it comes to R&D performance. Within the business sector, we will focus our study in the pharmaceutical sector, by selecting a number of large pharmaceutical companies. Pharmaceutical companies represent an interesting case of study, given that is it one of the most R&D intensive industries, while it si also known for its shift in R&D orientation, from an in-house focus in the development of R&D towards a model much more open and collaborative, with more interactions with academic partners and other companies. Despite the importance of industrial R&D, until now it remains relatively understudied how private sector institutions which are active in R&D have embraced the OA movement, hence it remains relatively unknown how the private sector adapts to and can benefit from the new paradigm of open scholarship. Our objective is to shed more light on the extent to which big pharma both has been publishing in OA and also has been benefiting from OA publications to build their own research.

Employers team up with higher education to bring open data and standardization to hiring

Walmart and the Lumina Foundation are helping to fund the group, which is dubbed the T3 Innovation Network. Created last year, the network’s goal is to use standardization about needed job skills, or competencies, and open data systems to “better align student, work-force and credentialing data with the needs of the economy.” …

The Jobs Data Exchange is an early part of the work.

That project, beginning in six states and Washington, D.C., features employers in health care, energy and the federal government’s Office of Personnel Management. Participants are working to use open data resources to more clearly define competency and credential requirements for jobs….”

Employers team up with higher education to bring open data and standardization to hiring

Walmart and the Lumina Foundation are helping to fund the group, which is dubbed the T3 Innovation Network. Created last year, the network’s goal is to use standardization about needed job skills, or competencies, and open data systems to “better align student, work-force and credentialing data with the needs of the economy.” …

The Jobs Data Exchange is an early part of the work.

That project, beginning in six states and Washington, D.C., features employers in health care, energy and the federal government’s Office of Personnel Management. Participants are working to use open data resources to more clearly define competency and credential requirements for jobs….”

For Innovation, Open Science Means Open for Business | Centre for International Governance Innovation

“Last week, Celgene – an American biotech company – invested the most ever for a Canadian-discovered early-stage drug. The US$40-million down and potentially US$1-billion deal only came about because of strategic funding by governments both for “open science” partnerships and for risk-taking, IP-generating research and commercialization centres. Open science partnerships openly share data and research results with the scientific community and do not seek patent rights over their results.

The Celgene deal is the fruit of a new innovation path – from open science to Canadian IP – that involves the Ontario government-funded Ontario Institute for Cancer Research (OICR) and its commercialization partner, FACIT Inc. This “made in Canada” approach does not copy U.S. approaches, which commonly result in Canadian IP rights being transferred to foreign firms for pennies on the dollar, as we are doing in the cases of Sidewalk Labs and investments in artificial intelligence. Rather, it leaves the IP in Canada for much longer, within a locally owned company that will continue to develop the drug and conduct clinical trials here, and thus extract fuller scientific and economic value from our investments….

Five years ago, OICR embraced open science as an early innovation strategy and partnered with the SGC. Both OICR and SGC appreciated that although IP is a key pillar of the innovation economy, seeking it too early or by the wrong entity creates barriers to collaboration, leads to redundant research, introduces significant transaction costs and, perhaps counterintuitively, slows down innovation. The open science collaboration allowed knowledge, materials and data to flow freely and enabled OICR and SGC to develop a new chemical probe against the WDR5 protein and to share it freely and rapidly with research groups around the world. Those groups revealed WDR5’s therapeutic role in leukemia, breast cancer and neuroblastoma….”